Dr Reddys Laboratories Ltd vs Hikal Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1322 as of 30 Apr 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Hikal Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Hikal Ltd?

Market cap of Dr Reddys Laboratories Ltd is 110,420 Cr while Market cap of Hikal Ltd is 2,340 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Hikal Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Hikal Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Hikal Ltd?

As of May 4, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1322.95. On the other hand, Hikal Ltd stock price is INR ₹189.85.

How do dividend payouts of Dr Reddys Laboratories Ltd and Hikal Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Hikal Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.